RxDoctor Payments Data

Brian Brady

Psychiatric/Mental Health · Baltimore, MDNPI 1225613094

Payments from drug & device makers

$3,218in general payments, 2019–2025

Across 158 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$719
  • Teva Pharmaceuticals USA, Inc.$587
  • E.r. Squibb & Sons, L.L.C.$371
  • Alkermes, Inc.$331
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$329
  • Johnson & Johnson$327
  • plus $555 from 5 others

What the payments were for

  • Food & beverage$3,08096%
  • Education$1394%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,218 in reported general payments places this provider in the 90th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$73,469
Medicare patients
71
Services billed
827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate40$116,857
Abilify MaintenaAripiprazole11$32,035
Fluphenazine Hcl129$24,336
LybalviOlanzapine/Samidorphan Malate13$21,292
Lurasidone Hcl60$18,108
Clozapine182$12,020
Fluphenazine Decanoate75$9,421
Aripiprazole72$9,032
Divalproex Sodium ErDivalproex Sodium92$5,756
Divalproex Sodium132$2,952
Benztropine Mesylate168$2,714
Quetiapine Fumarate147$2,691
Olanzapine111$2,604
Haloperidol76$2,428
Glycopyrrolate36$1,830

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$327$116,85740 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$178$32,03511 claims
Alkermes, Inc.Lybalvi$331$21,29213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →